Compare NGNE & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGNE | PGC |
|---|---|---|
| Founded | 2003 | 1921 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 836.7M |
| IPO Year | 2014 | 1997 |
| Metric | NGNE | PGC |
|---|---|---|
| Price | $34.41 | $46.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $63.57 | $40.50 |
| AVG Volume (30 Days) | ★ 310.4K | 220.8K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | 0.93 | ★ 13.51 |
| EPS | N/A | ★ 0.80 |
| Revenue | N/A | ★ $282,995,000.00 |
| Revenue This Year | N/A | $32.39 |
| Revenue Next Year | N/A | $12.64 |
| P/E Ratio | ★ N/A | $57.10 |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $15.93 | $24.45 |
| 52 Week High | $43.66 | $49.14 |
| Indicator | NGNE | PGC |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 53.61 |
| Support Level | $18.24 | $44.79 |
| Resistance Level | $37.27 | $47.18 |
| Average True Range (ATR) | 3.04 | 1.48 |
| MACD | -0.65 | -0.19 |
| Stochastic Oscillator | 17.67 | 63.90 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.